Congress Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $378K | Buy |
|
|||||
|
2025
Q2 | – | Sell |
|
|||||
|
2025
Q1 | $261K | Buy |
|
|||||
|
2024
Q3 | – | Sell |
|
|||||
|
2024
Q2 | $393K | Buy |
|
|||||
|
2023
Q4 | – | Sell |
|
|||||
|
2023
Q3 | $476K | Sell |
|
|||||
|
2023
Q2 | $544K | Sell |
|
|||||
|
2023
Q1 | $93.1M | Buy |
|
|||||
|
2022
Q4 | $110M | Sell |
|
|||||
|
2022
Q3 | $116M | Buy |
|
|||||
|
2022
Q2 | $105M | Sell |
|
|||||
|
2022
Q1 | $104M | Buy |
|
|||||
|
2021
Q4 | $77.4M | Sell |
|
|||||
|
2021
Q3 | $97M | Buy |
|
|||||
|
2021
Q2 | $92.3M | Buy |
|
|||||
|
2021
Q1 | $87.7M | Buy |
|
|||||
|
2020
Q4 | $72.9M | Sell |
|
|||||
|
2020
Q3 | $73.8M | Buy |
|